Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial

Tefera Agizew, Violet Chihota, Sambayawo Nyirenda, Zegabriel Tedla, Andrew F Auld, Unami Mathebula, Anikie Mathoma, Rosanna Boyd, Anand Date, Sherri L Pals, Phenyo Lekone, Alyssa Finlay, Tefera Agizew, Violet Chihota, Sambayawo Nyirenda, Zegabriel Tedla, Andrew F Auld, Unami Mathebula, Anikie Mathoma, Rosanna Boyd, Anand Date, Sherri L Pals, Phenyo Lekone, Alyssa Finlay

Abstract

Background: Xpert® MTB/RIF (Xpert) has high sensitivity for diagnosing tuberculosis (TB) compared to sputum-smear microscopy (smear) and can reduce time-to-diagnosis, time-to-treatment and potentially unfavorable patient-level treatment outcome.

Methods: People living with HIV (PLHIV) initiating antiretroviral therapy at 22 HIV clinics were enrolled and underwent systematic screening for TB (August 2012-November 2014). GeneXpert instruments were deployed following a stepped-wedge design at 13 centers from October 2012-June 2013. Treatment outcomes classified as an unfavorable outcome (died, treatment failure or loss-to-follow-up) or favorable outcome (cured and treatment completed). To determine outcome, smear was performed at month 5 or 6. Empiric treatment was defined as initiating treatment without/before receiving TB-positive results. Adjusting for intra-facility correlation, we compared patient-level treatment outcomes between patients screened using smear (smear arm)- and Xpert-based algorithms (Xpert arm).

Results: Among 6041 patients enrolled (smear arm, 1816; Xpert arm, 4225), 256 (199 per 2985 and 57 per 1582 person-years of follow-up in Xpert and smear arms, respectively; adjusted incidence rate ratio, 9.07; 95% confidence interval [CI]: 4.70-17.48; p < 0.001) received TB diagnosis and were treated. TB treatment outcomes were available for 203 patients (79.3%; Xpert, 157; smear, 46). Unfavorable outcomes were reported for 21.7% (10/46) in the smear and 13.4% (21/157) in Xpert arm (adjusted hazard ratio, 1.40; 95% CI: 0.75-2.26; p = 0.268). Compared to smear, in Xpert arm median days from sputum collection to TB treatment was 6 days (interquartile range [IQR] 2-17 versus 22 days [IQR] 3-51), p = 0.005; patients with available sputum test result had microbiologically confirmed TB in 59.0% (102/173) versus 41.9% (18/43), adjusted Odds Ratio [aOR], 2.00, 95% CI: 1.01-3.96, p = 0.048). In smear arm empiric treatment was 68.4% (39/57) versus 48.7% (97/199), aOR, 2.28, 95% CI: 1.24-4.20, p = 0.011), compared to Xpert arm.

Conclusions: TB treatment outcomes were similar between the smear and Xpert arms. However, compared to the smear arm, more patients in the Xpert arm received a TB diagnosis, had a microbiologically confirmed TB, and had a shorter time-to-treatment, and had a lower empiric treatment. Further research is recommended to identify potential gaps in the Botswana health system and similar settings.

Trial registration: ClinicalTrials.gov Identifier: NCT02538952. Retrospectively registered on 2 September 2015.

Keywords: Outcome; Smear; Treatment; Tuberculosis; Xpert MTB/RIF.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Enrollment*, screening by smear or by Xpert MTB/RIF, and TB diagnosis in Botswana

References

    1. Boehme C, Nabeta P, Hillemann D, Nicol P, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–1015. doi: 10.1056/NEJMoa0907847.
    1. Boehme C, Nicol M, Nabeta P, Michael S, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–1505. doi: 10.1016/S0140-6736(11)60438-8.
    1. Botswana S. Botswana Aids impact survey IV (BAIS IV) 2013.
    1. Ansari A, Kombe H, Kenyon A, Hone M, Tappero W, Nyirenda T, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997–1998. Int J Tuberc Lung Dis. 2002;6(1):55–63.
    1. Gupta K, Lucas B, Fielding L, Lawn D. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29:1987–2002. doi: 10.1097/QAD.0000000000000802.
    1. Botswana National Tuberculosis Program (BNTP) Manual, Ministry of Health, Botswana. 2011.
    1. Lawn S, Nicol M, Corbett E. Effect of empirical rx on outcomes of clinical trials of dx assays for TB. Lancet Inf Dis. 2015;15(1):17–18. doi: 10.1016/S1473-3099(14)71049-7.
    1. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Frank Cobelens F, et al. Impact on patients’ treatment outcomes of Xpert MTB/RIF implementation for the diagnosis of tuberculosis: follow-up of a stepped-wedge randomized clinical trial. PLoS One. 2015;10(4):e0123252. doi: 10.1371/journal.pone.0123252.
    1. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLOS Med. 2014;11(12):e1001766. doi: 10.1371/journal.pmed.1001766.
    1. Cox H, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med. 2014;11(11):e1001760. doi: 10.1371/journal.pmed.1001760.
    1. Fielding K, Mccarthy K, Ginindza S, Chihota V, Charalambous S, Churchyard G, et al, A grant. Treatment outcome participant in the XTEND trial. Abstract OA-386-05. 46th Conference on Lung Health, Liverpool, Cape Town, South Africa 2–6 December 2015.
    1. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14:527–532. doi: 10.1016/S1473-3099(13)70360-8.
    1. Auld AF, Agizew T, Pals S, Finlay A, Ndwapi N, Boyd R, et al. Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality. BioMed Central Infect Dis. 2016;16(1):606. doi: 10.1186/s12879-016-1905-4.
    1. Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T, et al. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2009;50(5):537–545. doi: 10.1097/QAI.0b013e318196761c.
    1. World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: WHO; 2010. ISBN: 978 92 4 150070 8.
    1. World Health Organization . Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) 2013.
    1. StataCorp . Stata statistical software: release 14. College Station: StataCorp LP; 2015.
    1. CONSORT . Checklist of information to include when reporting a randomised trial. 2010.
    1. Agizew T, Boyd R, Ndwapi N, Auld A, Basotli J, Nyirenda S, et al. Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana. PLoS One. 2017;12(8):e0183237. doi: 10.1371/journal.pone.0183237.
    1. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383:424–435. doi: 10.1016/S0140-6736(13)62073-5.
    1. Yoon C, Cattamanchi A, Davis J, Worodria W, Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One. 2012;7(11):e48599. doi: 10.1371/journal.pone.0048599.
    1. Calligaro G, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Resp Med. 2015;3:621–630. doi: 10.1016/S2213-2600(15)00198-8.
    1. Churchyard G, Stevens W, Mametja L, McCarthy M, Chihota V, Nicol M, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in south African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015;3:e450–e457. doi: 10.1016/S2214-109X(15)00100-X.
    1. Auld A, Agizew T, Mathoma A, Boyd R, Date A, Pals S, et al. Effect of TB screening and retention interventions on early ART mortality in Botswana. Oral abstract 31, 25th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts. 2018.
    1. Stop TB Partnership’s New Diagnostics Working Group/World Health Organization . Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva: World Health Organization; 2009.
    1. World Health Organization, Monitoring of Xpert MTB/RIF roll-out. Accessed 21 July 2017. Available from
    1. The World Health Organizations global tuberculosis report 2017, WHO.
    1. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the TEMPRANO ANRS 12136 trial. Lancet Glob Health. 2017;5:e1080–e1089. doi: 10.1016/S2214-109X(17)30372-8.
    1. The World health organization . Latent tuberculosis infection Updated and consolidated guidelines for programmatic Management, WHO/CDS/TB/2018.4. 2018.
    1. Sun A, Denkinger C, Dowdy D. Understanding the diagnostic cascade of tuberculosis: insight from a transmission model. Abstract OAP-314-31. 45th Conference on Lung Health, Barcelona, Spain, 28 October – 1 November 2014.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner